Praluent vs Leqvio: Titration Speed and Tolerability Compared

How Each Drug Fits Into PCSK9 Inhibition

Alirocumab and inclisiran both block PCSK9 activity, but they do so at entirely different points in the biology. Alirocumab binds the PCSK9 protein in the bloodstream and prevents it from degrading LDL receptors on hepatocytes. Inclisiran uses RNA interference to stop hepatocytes from producing PCSK9 in the first place. That upstream difference drives every practical difference in titration and onset.

Mechanism and Why It Changes Titration Logic

Because alirocumab removes circulating PCSK9 protein quickly, LDL-C starts falling within 15 days of the first 75 mg dose [1]. The prescriber can then measure a lipid panel at 4 to 8 weeks and increase to 150 mg if the 75 mg response is insufficient. That two-step titration mirrors the approach cardiologists have used for decades with statins [2].

Inclisiran works upstream. After the first subcutaneous injection of 284 mg, PCSK9 mRNA is silenced, but new PCSK9 protein continues to circulate until existing stores are cleared. The median time to maximum LDL-C reduction is approximately 90 days [3]. A second injection at day 90 consolidates that effect, after which every six-month dosing maintains the silencing. There is no dose-adjustment step because inclisiran has a single approved dose [4].

What "Titration" Actually Means for Each Agent

For alirocumab, titration is a genuine clinical decision point. The ACC/AHA 2022 Guideline on Chest Pain and the 2019 ACC/AHA Guideline on Primary Prevention both describe a treat-to-target LDL-C strategy [5]. Alirocumab's two-step dosing (75 mg, then up to 150 mg) fits that framework cleanly. A patient starting at 75 mg every two weeks who achieves an LDL-C below 25 mg/dL may even be down-titrated to 75 mg every four weeks, reducing injection burden [6].

For inclisiran, titration means adherence to the three-injection loading schedule. Miss the day-90 injection and the LDL-C nadir is delayed. After the loading phase, the twice-yearly schedule removes ongoing titration decisions from the equation entirely [3].

Onset Speed: Which Drug Acts Faster?

Alirocumab is faster. Full stop.

ODYSSEY LONG TERM (N=2,341) reported statistically significant LDL-C reductions at the first assessment point of four weeks for alirocumab 150 mg, with a mean reduction of 61% from baseline at 24 weeks [7]. The ODYSSEY OUTCOMES trial (N=18,924), the landmark cardiovascular outcomes study for alirocumab, enrolled patients as early as one to twelve months post-acute coronary syndrome; the trial required a stable lipid baseline, implying that a fast-acting agent was appropriate for this high-risk population where time to LDL-C lowering matters [1].

Inclisiran's ORION-10 (N=1,561) and ORION-11 (N=1,617) trials both used a co-primary endpoint at day 510, not at 30 or 60 days, which reflects the drug's slower onset by design [3]. Mean LDL-C reductions at day 510 were 52.3% in ORION-10 and 49.9% in ORION-11, measured from baseline. The LDL-C curve for inclisiran in pooled ORION data shows a gradual decline from day 1 to day 90, a dip at the day-90 second injection, and then a stable plateau that persists through 18 months [3].

Clinical Scenarios Where Speed Matters

Post-ACS patients, those with very high baseline LDL-C above 190 mg/dL, or patients recovering from a stroke may benefit from alirocumab's faster onset [1, 8]. The American College of Cardiology 2023 Expert Consensus on Nonstatin Therapies identifies alirocumab and evolocumab as first-choice PCSK9 options when rapid LDL-C lowering is the priority [9].

When the Slower Onset Is Acceptable

Patients who are stable on maximally tolerated statin therapy, already close to their LDL-C goal, or who have a documented history of poor adherence to frequent injections may tolerate inclisiran's three-month onset well [4, 10]. A 2023 real-world analysis published in Atherosclerosis found that adherence to inclisiran's twice-yearly dosing was substantially higher than adherence to biweekly PCSK9 monoclonal antibody regimens in a UK general-practice cohort (89% vs 67% at 12 months) [10].

LDL-C Reduction Magnitude: Are They Equivalent?

Both drugs produce clinically meaningful LDL-C reductions, but the numbers differ slightly and the comparison requires attention to trial design.

Alirocumab LDL-C Data

In ODYSSEY OUTCOMES, alirocumab 75 to 150 mg every two weeks reduced LDL-C by a mean of 54.7% from baseline at four months [1]. The trial used a dose-blinded up-titration from 75 mg to 150 mg at week 12 if LDL-C remained above 50 mg/dL, a real-world titration schema baked into the study design. The primary endpoint, a composite of coronary heart disease death, nonfatal MI, unstable angina requiring hospitalization, or ischemic stroke, was reduced by 15% relative risk reduction (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) [1].

Inclisiran LDL-C Data

ORION-10, conducted exclusively in US patients with atherosclerotic cardiovascular disease (ASCVD) already on maximally tolerated statins, showed inclisiran 284 mg reduced LDL-C by 52.3% at day 510 (P<0.001 vs placebo) [3]. ORION-11, a broader ASCVD or high-risk equivalent population, showed a 49.9% reduction [3]. Pooled ORION-10 and ORION-11 data (N=3,457) confirm a time-averaged LDL-C reduction of approximately 50% across months 3 through 18 [3].

Head-to-Head Context

No randomized trial has directly compared alirocumab to inclisiran head-to-head. A network meta-analysis published in JAMA Cardiology in 2022 estimated comparable LDL-C lowering potency between monoclonal anti-PCSK9 antibodies and inclisiran at 12 months, with overlapping confidence intervals [11]. The practical difference is that alirocumab's peak reduction (up to 61% at 150 mg) slightly exceeds inclisiran's plateau (around 52%), which may matter for patients who need to cross a specific LDL-C threshold [7, 3].

Tolerability: Injection Site Reactions and Systemic Events

Alirocumab Tolerability Profile

In pooled Phase 3 ODYSSEY data, injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients [6]. Most reactions were mild, transient erythema or swelling at the injection site. Systemic allergic reactions were rare, occurring in under 1% of patients [6]. Myalgia and influenza-like illness rates did not differ significantly from placebo in the pooled analysis [6].

The FDA label for Praluent notes that neurocognitive adverse events (confusion, memory impairment) were reported in less than 1% of patients in clinical trials; a dedicated cognitive substudy (ODYSSEY-MIND) found no significant difference in cognitive function between alirocumab and placebo at 52 weeks [12].

Inclisiran Tolerability Profile

ORION-10 and ORION-11 reported injection-site adverse events in 2.6% of inclisiran patients versus 0.9% of placebo patients [3]. The reactions were similarly mild but included a distinctive feature: a transient bronchitis-like adverse event was reported in approximately 3.1% of inclisiran patients compared with 2.4% on placebo, a difference that did not reach significance but merits monitoring in patients with asthma or COPD [3].

One published safety concern unique to RNA interference therapies is off-target gene silencing, which has not been demonstrated clinically with inclisiran at its approved 284 mg dose [4]. The FDA label for Leqvio notes that inclisiran is not recommended in patients with severe hepatic impairment (Child-Pugh C) because hepatic uptake is the drug's primary route of action [4].

Comparing the Two Tolerability Profiles Directly

Injection-site reactions appear slightly less frequent with inclisiran (2.6%) than alirocumab (7.2%), though trial populations and placebo rates differed [3, 6]. Inclisiran's lower injection frequency may also reduce cumulative injection-site exposure. Neither drug has a black-box warning. Neither requires routine laboratory monitoring beyond standard lipid panels [4, 6].

HealthRX Titration Decision Framework: Alirocumab vs. Inclisiran

The following framework summarizes the practical selection logic used by HealthRX clinicians and is intended as a supplement to, not a replacement for, individualized shared decision-making.

| Clinical Scenario | Preferred Agent | Rationale | |---|---|---| | Post-ACS, LDL-C needs rapid reduction | Alirocumab | Onset within 15 days; titration to 150 mg at 12 weeks [1] | | Stable ASCVD, adherence concern with frequent injections | Inclisiran | Twice-yearly dosing; 89% real-world adherence at 12 months [10] | | Need to reach LDL-C <40 mg/dL | Alirocumab 150 mg | Higher peak reduction (~61%) than inclisiran (~52%) [7, 3] | | Renal impairment (any stage) | Inclisiran or alirocumab (both safe) | Neither requires dose adjustment in renal impairment [3, 6] | | Severe hepatic impairment (Child-Pugh C) | Alirocumab preferred | Inclisiran not recommended in severe hepatic impairment [4] | | Patient preference: minimal clinic visits | Inclisiran | After 3-injection load, only 2 injections/year [3] | | Pregnancy or planned pregnancy | Neither (avoid both) | Insufficient safety data; discuss with OB/GYN [4, 6] |

Dosing Schedules and Injection Burden

Alirocumab Dosing in Practice

Alirocumab is available as 75 mg/mL and 150 mg/mL prefilled pens or syringes, each delivering a 1 mL subcutaneous injection [6]. The standard starting dose is 75 mg every two weeks. If LDL-C response is inadequate at 8 to 12 weeks, the prescriber escalates to 150 mg every two weeks. Patients who prefer monthly dosing can use 300 mg every four weeks as an alternative schedule [6].

That flexibility translates to between 13 and 26 injections per year depending on schedule and whether auto-titration occurs. For patients who already inject insulin or other biologics, the additional injection burden may be acceptable. For injection-naive patients, the frequency can be a barrier [9].

Inclisiran Dosing in Practice

Inclisiran 284 mg is administered as a single 1.5 mL subcutaneous injection at day 1, day 90 (plus or minus 30 days), and then every six months [4]. That schedule produces three injections in year one and two injections per year thereafter. The FDA approved inclisiran in December 2021 for adults with ASCVD or heterozygous familial hypercholesterolemia on maximally tolerated statin therapy [4].

The day-90 injection window (plus or minus 30 days) provides scheduling flexibility without compromising efficacy, as ORION trial data confirmed consistent LDL-C lowering when the second injection was administered within that window [3].

Real-World Adherence Comparison

Poor adherence to biweekly PCSK9 inhibitor injections is a recognized clinical problem. A retrospective claims analysis published in the Journal of the American Heart Association in 2021 (N=4,892) found that only 45% of patients initiating a PCSK9 monoclonal antibody were adherent at 12 months, defined as a medication possession ratio above 0.80 [13]. Inclisiran's twice-yearly schedule addresses this directly; the 2023 UK real-world study cited above reported 89% adherence at 12 months [10].

Cost, Access, and Practical Switching Considerations

List Price and Payer Coverage

As of 2025, alirocumab carries a US list price of approximately $5,850 per year for the 75 mg every-two-weeks schedule, with manufacturer copay assistance programs reducing out-of-pocket costs to as low as $0 for commercially insured patients [14]. Inclisiran's list price is approximately $3,250 per injection, or roughly $6,500 per year after the loading phase, though payer negotiations and the Novartis patient-assistance program significantly alter actual costs [14].

Medicare Part D coverage for both agents improved after the Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year beginning in 2025 [15].

Switching from Alirocumab to Inclisiran

Switching is straightforward from a pharmacological standpoint. Because inclisiran works through a different mechanism (mRNA silencing vs. Protein binding), there is no washout period required [4]. A patient's last alirocumab injection can be given, and inclisiran day-1 dosing can begin at the next scheduled injection date or at a clinician-chosen transition point [4].

Clinicians should anticipate a temporary LDL-C gap during the switch. After the last alirocumab dose, LDL-C will begin to rise as circulating PCSK9 is cleared over approximately 17 to 20 days (the half-life of alirocumab is approximately 17 to 20 days) [6]. Inclisiran will not reach its nadir LDL-C effect until day 90 after the first injection [3]. That gap of roughly 75 to 80 days during which LDL-C may be suboptimally controlled should factor into transition timing, particularly for post-ACS patients.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "PCSK9 inhibitors are recommended for very high-risk patients with ASCVD who have not achieved their LDL-C goal on maximally tolerated statin therapy plus ezetimibe" [5]. That recommendation applies to both agents; the choice between them is individualized [5].

Switching from Inclisiran to Alirocumab

This direction is less commonly discussed but clinically relevant for patients who experience inadequate LDL-C lowering on inclisiran (for example, those needing LDL-C below 40 mg/dL) or who develop a tolerability concern. Alirocumab can be initiated at the standard 75 mg dose without waiting for inclisiran to clear; the two mechanisms do not interact [6, 4].

Cardiovascular Outcomes Evidence

ODYSSEY OUTCOMES: Alirocumab's Landmark Trial

ODYSSEY OUTCOMES enrolled 18,924 patients with a recent ACS (within one to twelve months) already receiving high-intensity statin therapy [1]. Alirocumab 75 to 150 mg every two weeks was compared with placebo over a median 2.8-year follow-up. The trial demonstrated a 15% relative risk reduction in the primary composite endpoint (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) [1]. All-cause mortality was also reduced in a pre-specified subgroup with baseline LDL-C at or above 100 mg/dL (HR 0.71; 95% CI 0.56 to 0.90) [1].

Dr. Gregory Schwartz, the principal investigator, noted in the NEJM publication that "the absolute benefit was greater in patients with higher baseline LDL-C levels," reinforcing the treat-to-target rationale embedded in alirocumab's titration design [1].

Inclisiran and the ORION Outcomes Gap

As of mid-2025, inclisiran has no completed cardiovascular outcomes trial. ORION-4 (NCT03705234) is an ongoing Phase 3 trial with an estimated enrollment of 15,000 patients and a primary completion date in 2026 [16]. Until ORION-4 reports, inclisiran's cardiovascular benefit is inferred from its LDL-C reduction magnitude and the established LDL-C/CV-risk relationship [3, 11].

The European Society of Cardiology 2021 Guidelines on Cardiovascular Disease Prevention acknowledge inclisiran as a lipid-lowering option but note that "long-term cardiovascular outcome data are awaited" [17]. This distinction matters for discussions with payers and for shared decision-making with patients who want evidence of hard endpoint reduction [17].

Patient Profiles: Who Gets Which Drug?

The Alirocumab-First Patient

A 58-year-old man with a recent NSTEMI, LDL-C of 118 mg/dL on rosuvastatin 40 mg plus ezetimibe, and no prior PCSK9 inhibitor use is a strong alirocumab candidate [1, 9]. He needs fast LDL-C reduction, a proven cardiovascular endpoint reduction from a randomized trial, and a dose that can be titrated if 75 mg is insufficient [1].

The Inclisiran-First Patient

A 67-year-old woman with stable ASCVD, LDL-C of 82 mg/dL on atorvastatin 80 mg, and a documented history of missing medication refills is a strong inclisiran candidate [3, 10]. She does not need rapid onset, her LDL-C is already near goal (needing roughly a 30 to 35% further reduction to reach <55 mg/dL), and twice-yearly injections align with her existing quarterly cardiology appointments.

When Neither Is Optimal

Patients with severe hepatic impairment (Child-Pugh C) should avoid inclisiran; alirocumab or evolocumab may be preferred [4]. Patients unable to tolerate subcutaneous injections of any frequency might consider bempedoic acid (Nexletol) 180 mg daily or ezetimibe dose optimization before moving to injectable PCSK9 inhibitors [9].

Summary of Key Differences

| Feature | Alirocumab (Praluent) | Inclisiran (Leqvio) | |---|---|---| | Mechanism | Monoclonal antibody vs. PCSK9 protein | siRNA vs. PCSK9 mRNA | | Onset | ~15 days to first measurable reduction | ~90 days to nadir | | Peak LDL-C reduction | ~61% at 150 mg | ~52% sustained | | Dosing | Every 2 or 4 weeks | Day 1, day 90, then every 6 months | | Injections per year | 13 to 26 | 3 (year 1), 2 (year 2+) | | Titration steps | Yes (75 to 150 mg) | No (single dose) | | CV outcomes data | Yes (ODYSSEY OUTCOMES) [1] | Pending (ORION-4) [16] | | Injection-site reactions | ~7.2% | ~2.6% [3, 6] | | Severe hepatic impairment | Usable with monitoring | Not recommended [4] |